Aperio Group LLC boosted its stake in shares of Amedisys Inc (NASDAQ:AMED) by 65.0% during the second quarter, Holdings Channel reports. The fund owned 22,068 shares of the health services provider’s stock after buying an additional 8,694 shares during the period. Aperio Group LLC’s holdings in Amedisys were worth $1,386,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of AMED. BlackRock Inc. increased its stake in shares of Amedisys by 2,877.7% in the first quarter. BlackRock Inc. now owns 5,676,870 shares of the health services provider’s stock valued at $290,032,000 after buying an additional 5,486,225 shares in the last quarter. American Century Companies Inc. increased its stake in shares of Amedisys by 148.7% in the first quarter. American Century Companies Inc. now owns 1,200,754 shares of the health services provider’s stock valued at $61,347,000 after buying an additional 717,939 shares in the last quarter. Bank of New York Mellon Corp increased its stake in shares of Amedisys by 125.0% in the first quarter. Bank of New York Mellon Corp now owns 781,256 shares of the health services provider’s stock valued at $39,915,000 after buying an additional 433,956 shares in the last quarter. Norges Bank bought a new stake in shares of Amedisys during the fourth quarter valued at $13,483,000. Finally, Monarch Partners Asset Management LLC bought a new stake in shares of Amedisys during the first quarter valued at $8,984,000. 99.80% of the stock is owned by institutional investors and hedge funds.

Shares of Amedisys Inc (NASDAQ:AMED) traded up 1.35% during midday trading on Friday, hitting $48.88. The company had a trading volume of 352,034 shares. The stock’s 50-day moving average price is $56.08 and its 200-day moving average price is $54.19. Amedisys Inc has a 12 month low of $34.58 and a 12 month high of $65.91. The company has a market cap of $1.66 billion, a price-to-earnings ratio of 41.78 and a beta of 0.89.

Amedisys (NASDAQ:AMED) last released its quarterly earnings data on Wednesday, July 26th. The health services provider reported $0.62 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.50 by $0.12. Amedisys had a return on equity of 13.71% and a net margin of 2.70%. The business had revenue of $378.80 million during the quarter, compared to analyst estimates of $380.80 million. During the same quarter in the previous year, the firm posted $0.42 EPS. The business’s revenue for the quarter was up 5.0% compared to the same quarter last year. On average, equities research analysts forecast that Amedisys Inc will post $2.21 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Amedisys Inc (AMED) Shares Bought by Aperio Group LLC” was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another website, it was stolen and reposted in violation of U.S. and international copyright and trademark legislation. The original version of this piece can be viewed at https://www.dailypolitical.com/2017/08/13/amedisys-inc-amed-shares-bought-by-aperio-group-llc.html.

Several equities research analysts recently weighed in on the company. Zacks Investment Research raised Amedisys from a “hold” rating to a “buy” rating and set a $59.00 price target for the company in a report on Monday, April 17th. Royal Bank Of Canada reaffirmed a “hold” rating and set a $56.00 price target on shares of Amedisys in a report on Monday, June 5th. Stephens increased their price target on Amedisys from $50.00 to $54.00 and gave the stock an “equal weight” rating in a report on Thursday, May 4th. Benchmark Co. reaffirmed a “hold” rating and set a $57.00 price target (up from $50.00) on shares of Amedisys in a report on Wednesday, May 3rd. Finally, Mizuho downgraded Amedisys from a “buy” rating to a “neutral” rating and set a $50.00 price target for the company. in a report on Wednesday, July 26th. Six research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Amedisys presently has an average rating of “Hold” and an average price target of $56.50.

In other Amedisys news, insider David B. Pearce sold 1,000 shares of the business’s stock in a transaction on Tuesday, August 8th. The stock was sold at an average price of $50.00, for a total transaction of $50,000.00. Following the completion of the transaction, the insider now owns 10,488 shares in the company, valued at approximately $524,400. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Bruce D. Perkins purchased 2,000 shares of Amedisys stock in a transaction on Thursday, August 3rd. The shares were acquired at an average price of $46.60 per share, with a total value of $93,200.00. Following the transaction, the director now directly owns 15,825 shares in the company, valued at approximately $737,445. The disclosure for this purchase can be found here. Insiders own 2.80% of the company’s stock.

About Amedisys

Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.

Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys Inc (NASDAQ:AMED).

Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with MarketBeat.com's FREE daily email newsletter.